Tycel J Philips, MD
Brody J et al. Subcutaneous epcoritamab + GemOx in patients with relapsed or refractory DLBCL: Updated results from EPCORE NHL-2. ASCO 2024;Abstract 7037.
Brody J et al. Epcoritamab SC + GemOx Leads to high complete metabolic response rates in patients with relapsed/refractory diffuse large B‑cell lymphoma ineligible for autologous stem cell transplant: Updated results from Epcore NHL-2. ASH 2023;Abstract 3092.
Dickinson M et al. Glofitamab monotherapy in patients with relapsed/refractory large B-cell lymphoma: Extended follow-up and landmark analyses from a pivotal Phase II study. ICML 2023;Abstract 095.
Falchi L et al. Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data. ASCO 2023;Abstract 7519.
Hutchings M et al. Glofitamab monotherapy in relapsed or refractory large B-cell lymphoma: Extended follow-up from a pivotal phase II study and subgroup analyses in patients with prior chimeric antigen receptor T-cell therapy and by baseline total metabolic tumor volume. ASH 2023;Abstract 433.
Hutchings M et al. Glofitamab plus polatuzumab vedotin continues to demonstrate frequent and durable responses and has a manageable safety profile in patients with ≥2L relapsed/refractory DLBCL, including HGBCL, and in patients with prior CAR T-cell therapy: Updated results from a phase Ib/II study. ASH 2023;Abstract 4460.
Mazza IA et al. Subcutaneous epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma from EPCORE NHL-5. ASH 2023;Abstract 438.
Thieblemont C et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I/II trial. J Clin Oncol 2023;41(12):2238-47. Abstract
Topp MS et al. Glofitamab plus R-CHOP induces high response rates with a manageable safety profile in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): A 12-month analysis from a phase Ib study. ASH 2023;Abstract 3085.
Ian Flinn, MD, PhD
Falchi L et al. Subcutaneous (SC) mosunetuzumab (mosun) as first-line therapy for patients (pts) with high tumor-burden follicular lymphoma (FL): First results of a multicenter phase 2 study. ASH 2023;Abstract 604.
Linton K et al. Epcoritamab SC monotherapy leads to deep and durable responses in patients with relapsed or refractory follicular lymphoma: First data disclosure from the Epcore NHL-1 follicular lymphoma dose-expansion cohort. ASH 2023;Abstract 1655.
Lori LA et al. Epcoritamab with rituximab + lenalidomide (R2) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance in FL: EPCORE NHL-2 arms 6 and 7. ASCO 2024;Abstract 7014.
Morschhauser F et al. Preliminary findings of a phase Ib/II trial indicate manageable safety and promising efficacy for mosunetuzumab in combination with lenalidomide (m+len) in previously untreated (1L) Follicular Lymphoma (FL). ASH 2023;Abstract 605.
Schuster SJ et al. Mosunetuzumab monotherapy continues to demonstrate durable responses in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal phase II study. ASH 2023;Abstract 603.
Villaboas JC et al. Results of a second, prespecified analysis of the phase 2 study ELM-2 confirm high rates of durable complete response with odronextamab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) with extended follow-up. ASH 2023;Abstract 3041.
Joshua Brody, MD
Crombie JL et al. Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Blood 2024;143(16):1565-75. Abstract
Falchi L et al. Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns, and opportunities. Blood 2023;141(5):467-80. Abstract
Reynolds G et al. Infections following bispecific antibodies in myeloma: A systematic review and meta-analysis. Blood Adv 2023;7(19):5898-903. Abstract